Gilead buys cell therapy partner Arcellx for up to $7.8bn Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

#Gilead #celltherapy #Arcellx #GileadSciences #celltherapies #cancer #oncology #CARTtherapy #multiplemyeloma #Anitocel #CARexpression #BCMAtarget #BCMAdirectedCARTs #relapsedmultiplemyeloma #refractorymultiplemyeloma #iMMagine1study #multiplemyelomapatients #BCMAbindertechnology
zurl.co/iWAbv